Integration of 2D/3D deep learning and radiomics for predicting lymphovascular invasion in T1-stage invasive lung adenocarcinoma: a multicenter study

整合二维/三维深度学习和放射组学预测T1期浸润性肺腺癌淋巴血管侵犯:一项多中心研究

阅读:1

Abstract

INTRODUCTION: Accurate prediction of the lymphovascular invasion (LVI) status in patients with T1-stage invasive lung adenocarcinoma (LUAD) is crucial for treatment decision-making. Currently, there is a lack of highly efficient and precise prediction models. METHODS: In this retrospective study, 334 patients with T1-stage invasive LUAD who underwent radical surgery from four academic medical centers were included. Conventional radiomic features, two-dimensional deep learning (2D DL) features, and three-dimensional deep learning (3D DL) features were extracted from the tumor regions of the patients' CT images. Corresponding prediction models were constructed, and these features were integrated to develop a combined model for identifying the LVI status. The performance of the model was evaluated by calculating the area under the receiver operating characteristic (ROC) curve (AUC), and the net benefit of the models was compared using decision curve analysis (DCA). RESULTS: The combined model demonstrated excellent performance in distinguishing the LVI status, with its predictive ability superior to that of individual models. The AUC values for the training set, internal validation set, and external test set reached 0.958 (95% CI: 0.9294 - 0.9863), 0.886 (95% CI: 0.7938 - 0.9786), and 0.884 (95% CI: 0.8277 - 0.9401), respectively. DCA showed that the net benefit provided by the combined model was higher than that of other radiomic models. CONCLUSIONS: The combined model integrating radiomics, 2D DL, and 3D DL exhibits excellent performance in predicting the LVI status of patients with T1-stage invasive LUAD, and can provide key information for clinical treatment decision-making.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。